Habu, Takumi
Kumanishi, Ryosuke
Ogata, Takatsugu
Fujisawa, Takeshi
Mishima, Saori
Kotani, Daisuke
Kadowaki, Shigenori
Nakamura, Masaki
Hojo, Hidehiro
Fujiwara, Hisashi
Kumagai, Shogo
Koyama, Shohei
Fujita, Takeo
Kinoshita, Takahiro
Nishikawa, Hiroyoshi
Yano, Tomonori
Tajika, Masahiro
Muro, Kei
Mitsunaga, Shuichi
Kojima, Takashi
Bando, Hideaki
Article History
Received: 8 August 2022
Accepted: 22 January 2023
First Online: 8 February 2023
Declarations
:
: The study was performed according to the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. The study protocol was approved by the institutional review boards of the National Cancer Center (2021-222) and the Aichi Cancer Center (2021-0-086).
: Saori Mishima received honoraria from Merck Serono biopharma, and received research funding from Roche Diagnostics. Daisuke Kotani received honoraria from Takeda, Chugai Pharmaceutical, Lilly, MSD, Ono, Taiho Pharmaceutical, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer, and Merck Sereno biopharma, and received research funding from Ono Pharmaceutical, MSD, Novartis, Servier, Janssen, IQVIA, Syneos health, and Cmic Shiftzero. Shigenori Kadowaki received honoraria from Eli Lilly, Taiho Pharmaceutical, Ono Pharmaceutical, BMS, Chugai Pharmaceutical,Bayer, Merck Serono, Daiichi Sankyo and Eisai, and received research funding from Taiho Pharmaceutical, Eli Lilly, MSD, Chugai Pharmaceutical, Nobelpharma, Ono Pharmaceutical, Daiichi Sankyo and Yansen. Shohei Koyama received honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Chugai Pharmaceutical, and MSD, and received research funding outside the scope of this work from Bristol-Myers Squibb, Ono Pharmaceutical and Otsuka Pharmaceutical. Hiroyoshi Nishikawa received research funding and honoraria from Chugai Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb and MSD, and research funding from Taiho Pharmaceutical, Daiichi-Sankyo, Kyowa Kirin, Zenyaku Kogyo, Oncolys BioPharma, Debio pharma, Asahi-Kasei, Sysmex, Fujifilm, Rakuten Medical, SRL, Astellas Pharmaceutical, Sumitomo Dainippon Pharma and BD Japan outside of this study. Kei Muro received honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, Bristol-Myers Squibb, Eli Lilly and Daiichi Sankyo, and received research funding from Taiho, Eisai, Astellas, Amgen, Ono Pharmaceutical, MSD, Novartis, Chugai Pharmaceutical, Sanofi. He also received consulting fees from Astra Zeneca, Ono Pharmaceutical and Amgen. Takashi Kojima received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Covidien Japan, MSD, Taiho Pharmaceutical, Oncolys BioPharma, and received research funding from Ono Pharmaceutical, Bristol-Myers Squibb, BeiGene, EPS, MSD, Amgen, Shionogi, Chugai Pharmaceutical, Taiho Pharmaceutical, Parexel international and Merck Biopharma. Hideaki Bando received research funding from Ono Pharmaceutical and honoraria from Taiho Pharmaceutical and Eli Lilly Japan. Hiroyuki Nishikawa is an editorial board member. Takumi Habu, Ryosuke Kumanishi, Takatsugu Ogata, Takeshi Fujisawa, Masaki Nakamura, Hidehiro Hojo, Hisashi Fujiwara, Shogo Kumagai, Takeo Fujita, Takahiro Kinoshita, Tomonori Yano, Masahiro Tajika and Shuichi Mitsunaga declare that they have no conflict of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.